Navigation Links
Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Date:7/9/2013

BURLINGTON, Mass., July 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists indicate that overall survival is the factor that most influences their prescribing decisions for unresectable malignant melanoma, and that increased overall survival is associated with the highest level of unmet need. Interviewed thought-leaders are optimistic that Bristol-Myers Squibb/Ono Pharmaceuticals' nivolumab and GlaxoSmithKline's Tafinlar plus GlaxoSmithKline's Mekinist, in particular, will show advantages over sales-leading ipilimumab (Bristol-Myers Squibb's Yervoy) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled As Vemurafenib and Ipilimumab Gain Traction in the Market, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? finds that surveyed U.S managed care organization (MCO) pharmacy directors demand that emerging therapies provide significant improvements in overall survival over vemurafenib (Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf) to justify their cost and secure reimbursement. Vemurafenib is the premium-priced standard-of-care in unresectable malignant melanoma patients harboring the V600 BRAF mutation. Notably, a third of surveyed payers would not reimburse a new therapy priced the same as vemurafenib or higher that offers a six-month improvement in overall survival over vemurafenib, citing insufficient overall clinical benefit as one of the key reasons for not granting reimbursement.

The report also finds that surveyed U.S. and European oncologists identified hematological toxicity as the safety
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
4. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
5. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
6. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
7. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
8. Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines
9. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... July 29, 2014 According to ... "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ENT Navigation ... Size, Share, Growth, Trends and Forecast, 2014 - 2020", ... USD 218.5 million in 2013 and is expected to ... 2020, to reach an estimated value of USD 295.5 ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... (NASDAQ: THOR), a world leader in device-based mechanical circulatory ... said today it will be participating in the Oppenheimer ... 13. Taylor C. Harris, Senior Director of ... on the company, beginning at 10:15 a.m., Eastern Standard ...
... Dec. 9, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, announced that Care360™, the company,s ... e-Prescribing software system by Black Book Rankings, a leading ... services and software industries. Black Book ...
Cached Medicine Technology:Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 2Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 3
(Date:7/29/2014)... 29, 2014 Winter is here down ... afternoon in Sydney’s central business district. That is, until ... costume transformed the otherwise ordinary day into a celebration—a ... are ardent advocates of The Truth About Drugs, a ... Scientology . They woke up the city with a ...
(Date:7/29/2014)... DailyGossip.org reveals in its latest review that the new method ... patients and what they have to go through when cold ... of the new program. Ellie claims that she suffered from ... her very own research. Four years passed until she reached ... Get Rid of Cold Sores program claims that she was ...
(Date:7/29/2014)... Regardless of the good things that happen ... share those with. Love is about understanding, commitment and ... is also about overcoming all the challenges that a ... relationship, women need to know how to understand guys. ... program, please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Want young children ... them something that,s healthy is good for them. Doing ... good, a new study suggests. "Parents and caregivers ... may be better off simply serving the food without ... yummy the food actually is," said study authors Michal ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2
... ... Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for ... ... 10, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome side effects ...
... TUCSON, Ariz. , March 10 If ... of continuing medical education (CME) used by physicians will be ... dramatic increase over the 9% of CME delivered via the ... the winter, 2010 issue of the Journal of Continuing ...
... ... Registered Dietitian Day on March 10, the team behind Skinny in ... combining the best diet and nutrition information with the latest fashion ... ) online directory. Spearheaded by celebrity dietitian Tanya Zuckerbrot, M.S., ...
... ... ... -- A week from today, the Boston branch of the Harvard Business School Alumni ... co-founder Mike “Zappy” Zapolin will be in attendance to present the new website’s business ...
... ... ... ... ...
... may be able to safely lower the platelet ... patients without risking increased bleeding, according to new ... other medical institutions. Reducing platelet transfusions, and ... could help address frequent shortages in platelet supplies, ...
Cached Medicine News:Health News:Thyroid Hormone Analogue for Treating High Cholesterol 2Health News:Thyroid Hormone Analogue for Treating High Cholesterol 3Health News:Study Predicts Half of Physician Continuing Education Will Be Online by 2016 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 3Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 4Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 2Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 4Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 5Health News:Fewer platelets could be used for some cancer and bone-marrow transplantation patients 2
... With a zoom ratio of ... 0.75X to 11.25X, and the ... intervals from 1X to 11X, ... Magnifications of 3.75X to 540X ...
Inquire...
... apochromatically corrected objectives for ... most exacting demands in ... suitable for visual field ... mm and feature sufficiently ...
... working distances with high Numerical Apertures, these ... optical aberrations throughout the visible spectrum from ... across the entire 25mm field of view. ... colour reproduction, plus resolving power at the ...
Medicine Products: